Integration delays cut growth outlook, but buybacks lift EPS guidance

The quarter beat published expectations, but the quality of the beat was uneven. Revenue was $570.3 million versus published consensus of roughly $565 million, while adjusted EPS was $1.76 versus roughly $1.28 expected. The EPS upside was helped by a lower share count, a lower tax rate and a $25 million litigation-settlement benefit embedded in “other items,” so it was not purely operating strength. (Appendix B1 — Reconciliation of Consolidated Statement of Income Items; Appendix B Tickmarks)

The underlying growth engines were split sharply. Vascular grew 8.0% and Surgical grew 9.2% on a pro forma constant-currency basis, both solid performances. Interventional, however, declined 1.0% on the same basis despite the acquired Vascular Intervention business, meaning the acquisition contributed reported scale but did not yet produce organic growth. (Global Product Category Revenue Review)

Management explicitly cut the revenue outlook because the Biotronik integration is taking longer than expected. Full-year pro forma adjusted constant-currency growth was reduced to 3.5%–4.5% from 4.5%–5.5%, and GAAP revenue-growth guidance was also reduced to 13.4%–14.4%. That is the clearest negative change in the filing: the market is now being asked to accept slower near-term execution from the acquired Interventional portfolio. (2026 Financial Guidance; Executive Overview)

The EPS upgrade is mostly a capital-allocation and timing offset, not a clean improvement in operating momentum. Adjusted EPS guidance rose to $6.90–$7.20 after a $250 million second-quarter repurchase and the planned additional $250 million accelerated repurchase, alongside roughly $800 million of intended debt reduction. Yet adjusted operating margin fell to 19.6% from 24.8%, while gross margin declined to 61.7% from 64.5%, reflecting tariffs, the lower-margin acquisition and higher operating expenses. (Appendix B1; Capital Allocation Strategy Update; 2026 Guidance Considerations)

Net: a genuine earnings beat, but the forward picture is mixed rather than broadly positive. Vascular and Surgical are outperforming, liquidity from the OEM divestiture supports buybacks and debt paydown, and new product milestones add longer-term optionality. But the central acquisition is still underperforming on an organic basis, revenue guidance was cut, and the EPS increase relies materially on financial actions and lower costs rather than stronger consolidated operating growth. (Q2 Performance Summary; Global Product Category Revenue Review; Capital Allocation Strategy Update)